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1 Drug description 
Generic/Brand name/ATC code:  
Cabazitaxel (XRP-6258)/Jevtana®/not yet available 
Developer/Company:  
Sanofi-Aventis 
Description:  
Cabazitaxel, a new molecular entity, is an anticancer drug which belongs to 
the taxanes. This novel taxane inhibits microtubules which are crucial for 
cell division. Cabazitaxel binds to tubulin and thus promotes the assembly 
of tubulin into microtubules while simultaneously inhibiting disassembling,  
resulting in the inhibition of mitosis and accordingly in cell death [1]. One 
characteristic of cabazitaxel is a low affinity for P-gylcoprotein, a multidrug 
resistance transporter, which can cause resistance to docetaxel, another tax-
ane which is the standard therapy for castration-resistant prostate cancer [2-
4]. In preclinical test and in initial clinical trial, cabazitaxel was active in 
docetaxel-sensitive and in docetaxel-resistant cancers [1]. 
Cabazitaxel is administered intravenously at a dose of 25mg/m² every three 
weeks. 10mg prednisone per os should be administered daily throughout the 
therapy with cabazitaxel. An injection kit, containing 60mg/1.5mL cabazi-
taxel, is available [5]. No explicit recommendation on the optimal treatment 
duration was found. 
2 Indication 
Cabazitaxel is indicated for the treatment of patients with castration-
resistant metastatic prostate cancer previously treated with a docetaxel-
containing treatment regimen. 
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3 Current regulatory status 
In January 2011, the European Medicines Agency’s (EMA) Committee for 
Medicinal Products for Human Use (CHMP) adopted a positive opinion for 
the marketing authorization for cabazitaxel in combination with prednisone 
or prednisolone for the treatment of patients with hormone refractory metas-
tatic prostate cancer previously treated with a docetaxel-containing regimen 
[6].  
The US Food and Drugs Administration (FDA) granted market authoriza-
tion for Jevtana® in combination with prednisone for the treatment of pa-
tients with castration-resistant metastatic prostate cancer previously treated 
with a docetaxel-containing treatment regimen in June 2010 [5].  
4 Burden of disease 
Prostate cancer is the most common cancer in Austrian men and the second 
most common cancer-related cause of death [7, 8]. Median age at diagnosis 
is 72 years. In 2008, about 4,400 men were newly diagnosed with this cancer 
and 1,200 died. In Germany, 60,100 patients were diagnosed with prostate 
cancer and 11,600 died in 2006 [9]. Due to widespread prostate-specific an-
tigen (PSA) testing, prostate cancer is mostly diagnosed at an early, asymp-
tomatic stage of disease, resulting in about 5% of patients diagnosed after 
the tumour has spread [8]. In Austria, disseminated disease was found in 
about 3.3% of patients, resulting in about 150 patients with metastatic pros-
tate cancer per year [8]. Applying the same numbers to Germany would re-
sult in about 2,000 patients with disseminated prostate cancer.  
Risk factors for developing prostate cancer include age, ethnicity, family his-
tory, diet and genetic factors such as mutations in BRCA1 and BRCA2 genes 
[10].   
If not detected by PSA screening, clinical findings include asymmetric areas 
of induration or frank nodules in the prostate during digital rectal examina-
tion, genitourinary symptoms (e.g. urinary urgency, nocturia, erectile dys-
functions) and, in the minority of patients, symptoms of metastatic disease. 
As prostate cancer mainly metastasises to bone, most common symptoms at 
this stage are bone pain. To establish diagnosis of prostate cancer, a his-
tologic examination should be performed [10].  
Staging is done by using the tumour, node, metastasis (TNM) system which 
provides information for choosing the initial therapy. Other factors which 
impact on the choice of initial therapy are life expectancy, comorbidities, 
therapeutic side-effects and patients’ preferences [11].  
Besides the TNM system, the Gleason score is used in addition to establish 
prognosis. This score is a histopathologic grading system which distin-
guishes well and poorly differentiated prostate tissue [11, 12].  By taking the 
TNM system, the Gleason score and pre-treatment PSA levels into account, 
five patient groups with different probabilities of cure can be derived [10]. 
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Prognosis strongly depends on the stage at diagnosis. If the tumour is con-
fined to the prostate gland, a median survival of more than 5 years can be 
expected. For locally advanced forms of prostate cancer, cure is rarely possi-
ble, but median survival is still about 5 years. Patients with metastasised 
tumours have a median survival of 1-3 years [12].   
5 Current treatment 
Metastatic prostate cancer is not curable; therefore the main objective of 
therapy for this stage is to maintain quality-of-life (QoL) and to control the 
disease [10]. Therapy includes: 
 Androgen deprivation therapy (ADT) (synonym: hormone therapy, 
castration) is the standard initial therapy for patients with metastatic 
prostate cancer. Surgical castration (synonym: orchiectomy) or medi-
cal castration using a luteinizing hormone-releasing hormone 
(LHRH) agonist is the optimal ADT. In addition, antiandrogens for 
at least 7 days should be administered either prior to or simultane-
ously to LHRH agonists to patients with metastases who are likely to 
develop symptoms associated with an initial increase in testosterone 
(“flare”) with LHRH-agonists only [7, 12].  
In nearly all cases, disease progresses on ADT. If PSA level rises despite cas-
trate levels of testosterone  (serum testosterone < 20-50 ng/dl) the cancer is 
called “castrate-resistant”, “hormone-refractory” or “androgen-independent” 
[10]. Systemic therapy options for men with metastatic prostate cancer are 
then: 
 Multiple and sequential secondary hormone therapy including with-
drawal of ADT, antiandrogen therapy, cytochrome P450 inhibitors, 
oestrogens and corticosteroids. Even though no improvements in sur-
vival have been demonstrated for this therapies, the favourable toxic-
ity profile justifies their use before the administration of chemothera-
pies [10, 13].  
 Chemotherapy: 
  As 1st-line chemotherapy the combination of docetaxel and predni-
sone showed improved overall survival and improved QoL in com-
parison to mitoxantrone and prednisone [2, 10, 14, 15]. Therefore 
docetaxel is the standard of care for the initial chemotherapy in 
men with castration-resistant prostate cancer [4, 10, 13-15].  
 Because the combination of mitoxantrone and prednisone com-
pared with prednisone alone achieved pain reduction in patients 
with bony metastases, mitoxantrone might also be used as 1st -line 
chemotherapy [10, 11, 13] which is considered appropriate for pa-
tients with slowly progressing disease and those who are averse to 
adverse effects of docetaxel [16].  
 2nd-line chemotherapy needs to be considered after docetaxel ther-
apy has failed. Guidelines are tentative in giving a clear recom-
mendation of what should be applied next. Even though the com-
bination of mitoxantrone and prednisone can be considered de fac-
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to 2nd-line chemotherapy its impact on survival within this setting 
remains unclear [2, 10, 11].   
 Immunotherapy with sipuleucel-T has demonstrated prolonged 
overall survival for minimally symptomatic patients with castrate-
resistant prostate cancer and is therefore indicated for minimally 
symptomatic/asymptomatic and chemotherapy-naïve patients [11].   
 Symptom palliation for advanced prostate cancer is mainly done by 
systemic therapy, which includes analgesics, radiation therapy and 
bisphosphonates for bone metastases [12].  
For further lines of therapies, no standard exists. Patients might then be in-
cluded into clinical trials [11].   
6 Evidence 
In addition to a free text search including the websites of the EMA and the 
US FDA, a systematic literature search was conducted in PubMed, EM-
BASE and the Centre for Review and Dissemination Database on the 13th of 
December 2010. Search terms included were “Prostatic Neoplasms”, “pros-
tate cancer”, “XRP-6258”, “jevtana” and “cabazitaxel”.   
44 relevant references were identified of which one phase III study, the 
TROPIC trial, was included [17].   
6.1 Efficacy and safety - Phase III studies 
Table 1: Summary of efficacy  
Study title  
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel 
treatment: a randomised open-label trial 
Study  
identifier 
NCT00417079, EFC6193, EudraCT: 2006-003087-59, TROPIC trial 
Phase III, randomized, multi-centre, multinational, open label, computer generated allocation schedule  Design 
Duration  Enrolment: January 2007 – October 2008  
Median follow-up: 12.8 months 
Cut-off date for final analysis: September 2009 
Hypothesis Superiority 
Intervention Cabazitaxel 25mg/m2 iv on day 1 of each 21 day cycle + 10mg prednisone/d, for a 
maximum of 10 cycles, 378 patients 
Treatment groups 
Control Mitoxantrone 12mg/m2 iv on day 1 of each 21 day cycle + 10mg prednisone/d, for 
a maximum of 10 cycles, 377 patients 
overall survival 
(primary outcome) 
OS time interval from date of randomisation to death due to any cause 
progression-free sur-
vival   
PFS time between randomisation and the first date of progression as meas-
ured by PSA progression, tumour progression, pain progression, or death 
time to tumour  
progression  
TTP number of months from randomisation until evidence of progressive dis-
ease (RECIST [18])  
Endpoints and def-
initions 
PSA progression  - increase of ≥25% over nadir PSA concentration provided that the increase 
in the absolute PSA value was ≥5 μg/L for men with no PSA response, or 
≥50% over nadir for PSA responders 
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pain progression  - increase in median present pain intensity (PPI) score of ≥1 point from the 
reference value or an increase of ≥25% in the mean analgesic score or re-
quirement for palliative radiotherapy 
pain response  - two point or greater reduction from baseline median PPI score without an 
increased analgesic score (AS) or a decrease of 50% or more in the AS 
without an increase in the PPI score, maintained at least for 3 weeks 
tumour response - for patients with measurable disease based on RECIST [18] 
 
PSA response  - a ≥50% reduction in serum PSA concentration, established only for pa-
tients with a serum PSA concentration of ≥20μg/L at baseline 
Results and analysis 
Analysis  
description 
Primary analysis: Intention-to-treat analysis, final analysis planned when 511 deaths had occurred 
Characteristics median age: mitoxantrone 67 years vs cabazitaxel 68 years,  
Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0 or 1: 
mitoxantrone 91% vs cabazitaxel 93%,  
median serum PSA concentration: mitoxantrone 128μg/L vs cabazitaxel 
144μg/L,  
Bone metastases: mitoxantrone 87% vs cabazitaxel 80%,  
Visceral metastases: mitoxantrone 25% vs cabazitaxel 25%,  
Measurable disease: mitoxantrone 54% vs cabazitaxel 53%,  
Pain at baseline: mitoxantrone 45% vs cabazitaxel 46% 
Inclusion pathologically proven prostate cancer with documented disease progression 
during or after completion of docetaxel treatment, ECOG PS  of 0–2,  previous 
and on-going castration by orchiectomy or LHRH agonists, or both; anti-
androgen withdrawal followed by progression had to have taken place at 
least 4 weeks (6 weeks for bicalutamide) before enrolment 
Analysis  
population 
Exclusion previous mitoxantrone therapy, radiotherapy to 40% or more of the bone 
marrow, or cancer therapy (other than LHRH analogues) within 4 weeks be-
fore enrolment 
Treatment group Control 
(mitoxantrone) 
Intervention 
(cabazitaxel) 
Number of subjects 377 378 
OS (months) 
median 
95% CI  
 
12.7 
11.6 to 13.7 
 
15.1 
14.1 to 16.3 
PFS (months) 
median 
95% CI 
 
1.4 
1.4 to 1.7 
 
2.8 
2.4 to 3.0 
TTP (months) 
median 
95% CI 
 
5.4 
2.3 to 10.0 
 
8.8 
3.9 to 12.0 
time to PSA progression 
(months) 
       median 
       95% CI 
 
3.1 
0.9 to 9.1 
 
6.4 
2.2 to 10.1 
time to pain progression 
(months) 
       median 
       95% CI 
 
 
not reached 
- 
 
 
11.1 
2.9 to not reached 
Number of subjects 204 201 
tumour response rate 
% 
95% CI 
 
4.4 
1.6 to 7.2 
 
14.4 
9.6 to 19.3 
Number of subjects 325 329 
Descriptive statis-
tics and estimate  
Variability 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PSA response rate 
        % 
        95%CI 
 
 
7.7 
3.7 to 11.8 
 
9.2 
4.9 to 13.5 
 
Horizon Scanning in Oncology 
8 LBI-HTA | 2011 
 
Number of subjects 168 174 
pain response rate  
% 
95% CI 
 
7.7 
3.7 to 11.8 
 
9.2 
4.9 to 13.5 
 
QoL Not reported Not reported 
Comparison groups  mitoxantrone vs cabazitaxel 
Hazard ratio 0.7 
95% CI 0.59 to 0.83 
OS 
P value  <0.0001 
Hazard ratio 0.74 
95% CI 0.64 to 0.86 
PFS 
P value  <0.0001 
Hazard ratio 0.61 
95%  CI 0.49 to 0.76 
TTP 
P value  <0.0001 
Hazard ratio 0.75 
95% CI 0.63 to 0.90 
time to PSA progression 
P value  0.001 
Hazard ratio 0.91 
95% CI 0.69 to 1.19 
time to pain progression 
P value  0.52 
Effect estimate per 
comparison 
QoL  Not reported 
 
 
 
Table 2:  Most frequent adverse events  
 TROPIC trial 
Grade (according to 
CTCAE version 3.0 [19]) 
Outcome Control  
(mitoxantrone) 
(n=371) 
Intervention  
(cabazitaxel) 
(n=371) 
    
Grade 5  
 
AE-associated deaths ≤30 
days  after last dose of study 
3 (1%) 18 (5%) 
Haematological 
Leukopenia, n (%) 343 (92%) 355 (96%) 
Anaemia, n (%)  302( 81%) 361 (97%) 
Neutropenia, n (%) 325 (88%) 347 (94%) 
Non-haematological 
Diarrhoe, n (%) 39 (11%) 173 (47%) 
Fatigue, n (%) 102 (27%) 136 (37%) 
Grades 1 – 4 
 
Nausea, n (%) 85 (23%) 127 (34%) 
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Haematological 
Neutropenia, n (%) 
   febrile neutropenia, n (%) 
215 (58%) 
5 (1%) 
303 (82%) 
28 (8%) 
Leukopenia, n (%) 157 (42%) 253 (68%) 
Anaemia, n (%) 18 (5%) 39 (11%) 
Non-haematological 
Diarrhoe, n (%) 1 (<1%) 23 (6%) 
Fatigue, n (%) 11 (3%) 18 (5%) 
Grades ≥3  
Asthenia, n (%) 9 (2%) 17 (5%) 
 
The TROPIC trial, a phase III study, investigated cabazitaxel + prednisone 
in comparison to mitoxantrone + prednisone in 755 men suffering from cas-
tration-resistant metastatic prostate cancer who had received previous hor-
mone therapy, but had progressed during docetaxel containing therapy. The 
majority of patients had a good functional status (ECOG PS 0 or 1) and were 
slightly younger than patients usually are at diagnosis.  
Median OS was 15.1 months in the cabazitaxel group and 12.7 months in the 
mitoxantrone group (HR=0.70, p<0.0001) and was thus significantly im-
proved. When patients were analysed according to their baseline characteris-
tics, patients with better performance status and those who progressed dur-
ing docetaxel therapy seemed to benefit more from cabazitaxel than patients 
with ECOG PS 2 and men whose disease progressed ≥3 months after do-
cetaxel. Improvements were also found for other outcomes, such as PFS, 
tumour and PSA response rate and time to tumour progression. No differ-
ences were found for pain-related outcomes measures. 
AEs, even of grade 3 and higher, were very frequent, with haematological be-
ing the most common ones. For example, grade ≥3 neutropenia occurred in 
82% of patients treated with cabazitaxel and in 58% of patients in the mi-
toxantrone group. Deaths within 30 days of last study drug dose were ob-
served twice as often in the taxane group (5%) than in the comparison group 
(2%). Of these, 1% in the mitoxantrone group and 5% in the cabazitaxel 
group were deaths related to AEs. Because febrile neutropenia grade ≥3 was 
observed in 7% and the most frequent cause of death in the cabazitaxel 
group was neutropenia, the study authors suggest careful monitoring, dose 
reductions and prophylactic treatment with granulocyte colony-stimulating 
factor (G-CSF) for the management of these toxicities.   
Twice as many patients in the cabazitaxel group completed study treatment 
in comparison to the mitoxantrone group, but more patients discontinued 
cabazitaxel treatment due to AEs than patients in the mitoxantrone arm 
(cabazitaxel 18% vs mitoxantrone 8%).  
TROPIC trial included 
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cancer and disease 
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6.2 Efficacy and safety - further studies 
No further studies were identified for the investigated indication. 
7 Estimated costs 
No price estimates for cabazitaxel are yet available for Austria. In the US, 
one vial containing 60mg cabazitaxel costs an estimated $ 9,600.- (≈ € 7,100) 
[20]. Applying these cost estimates and assuming an average number of six 
treatment cycles (median number of treatment cycles was six in the TROP-
IC trial) would result in total costs of € 42,600.- and in monthly costs of 
about € 9,500.-.  
As the FDA recommends prophylaxis with G-CSF in order to prevent infec-
tion-related deaths in patients prone to neutropenia complications (e.g. 
age>65 years, poor performance status, previous episodes of febrile neutro-
penia [5]) these costs have to be taken into account additionally.  
8 Ongoing research 
Only one phase III trial was identified on clinicaltrials.gov:  
NCT01254279: a single arm open-label phase III clinical trial to provide ear-
ly access to cabazitaxel in patients with metastatic hormone refractory pros-
tate cancer previously treated with a docetaxel-containing regimen and to 
document safety of cabazitaxel in these patients. Official completion date is 
December 2015, but the trial will end in individual countries when cabazi-
taxel becomes commercially available.  
Besides, four phase I/II trials were found on clinicaltrials.gov, most of which 
were safety studies.   
Acoording to post-marketing requirements (PMR) postulated by the FDA 
two further phase 3 randomized controlled trials have to be conducted with 
the final report to be submitted in 2018. Both studies are supposed to evalu-
ate OS as well as drug-related deaths and safety [21]: 
- PMR 1649-3 obliges the developer to conduct a comparison of 75mg/m2 
docetaxel plus prednisone with cabazitaxel 25mg/m2 plus prednisone and 
cabazitaxel 20mg/m2 plus prednisone as first-line chemotherapy in patients 
with hormone-refractory metastatic prostate cancer.  
- PMR 1649-4 obliges the developer to conduct a comparison of cabazitaxel 
25mg/m2 plus prednisone and cabazitaxel 20mg/m2 plus prednisone as sec-
ond-line chemotherapy in 1,222 patients with hormone-refractory metastatic 
prostate cancer previously treated with docetaxel. 
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9 Commentary  
Cabazitaxel received a positive opinion for market authorizations by EMA’s 
CHMP in January 2011 and was licensed by the FDA in June 2010. The ap-
proved indication is cabazitaxel in combination with prednisone for the 
treatment of patients with metastatic castration-resistant prostate cancer 
who were previously treated with a docetaxel-containing treatment regimen.  
The FDA’s decision was based on the results of the TROPIC trial, a phase 
III trial, which compared cabazitaxel and mitoxantrone in 755 patients with 
castration-resistant metastatic prostate cancer previously treated with do-
cetaxel. The median OS was prolonged by 2.4 months in patients who had 
received cabazitaxel in comparison to mitoxantrone. The relative risk of 
death was reduced by 30% (HR=0.70, p<0.0001), whereas the absolute risk 
reduction was 13% (74% died in the mitoxantrone group and 61% died in 
the cabazitaxel group). Similar results were found for other endpoints such 
as PFS. AEs, foremost haematological ones, were more frequent in the caba-
zitaxel group (e.g. grade ≥3 neutropenia in 82% in the taxane group vs 58% 
in the mitoxantrone group) and more patients discontinued therapy due to 
AEs in this group (cabazitaxel 18% vs mitoxantrone 8%). Additionally, twice 
as many patients died within 30 days of last study drug dose in the cabazi-
taxel group as in the control group (cabazitaxel 5% vs mitoxantrone 2%), of 
which 5% in the cabazitaxel group and 1% in the mitoxantrone group were 
related to AEs. The study authors mention that a reduced dose (20mg/m² in-
stead of 25mg/m²) might offer a means to reduce AEs, but this might com-
promise efficacy too. 
Docetaxel is the standard of care for patients with castration-resistant me-
tastatic prostate cancer but if disease progresses, therapeutic options are 
limited and no consensus on the best therapy exists [12]. Thus, new regi-
mens are clearly needed. Cabazitaxel has shown, for the first time, statisti-
cally significant increases in survival for the 2nd-line treatment of patients 
with castration-resistant metastatic prostate cancer. But it should be men-
tioned that the protocol of the TROPIC trial was amended after 59 patients 
to exclude patients previously receiving a cumulative docetaxel dose lower 
than 225 mg/m² [17]. As patients with rapid progression might represent the 
truly docetaxel-refractory subgroup and their omission can thus lead to an 
overestimation of cabazitaxel actitivity in doxetacel resistant patients.  
Even if cabazitaxel was the first therapy for which improvements in OS after 
docetaxel-failure were found, it should be mentioned, that an increase in OS 
was meanwhile also shown for another drug. Preliminary results of a phase 
III report improved results on OS for arbiraterone in docetaxel-pretreated 
patients (14.8 months abiraterone + prednisone vs 10.9 months placebo + 
prednisone). Considering the significant toxicity of cabazitaxel a compari-
son of cabazitaxel with abiraterone as 2nd -line therapy might be worthwhile 
in the future [22].   
Moreover, the gain in median OS by 2.4 months was achieved in comparison 
to mitoxantrone, a drug which offers advantages in terms of symptom pallia-
tion and can thus be considered de-facto standard 2nd line therapy, but has 
an unclear impact on survival itself [2, 10, 11]. Furthermore, an additional 
2.4 months in this difficult to treat disease offers an incremental benefit, but 
a more distinct increase in OS might be derived if cabazitaxel was used in 
cabazitaxel received 
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licensed in the US 
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haematologic ones 
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in the meantime: OS 
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comparison to 
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the 1st-line setting. The comparison of cabazitaxel to docetaxel in the front-
line setting is thus of great interest.  
In addition, these results have to be balanced against serious and very fre-
quent AEs, as the gains in OS might come at the expenses of QoL, an out-
come for which, despite planned trials, no results are available yet [17]. 
Based on the results of the TROPIC trial, elderly patients aged ≥65 years 
seemed to be even more likely to experience certain AEs (e.g. neutropenia, 
asthenia, pyrexia) than younger patients [5]. Since patients in this trial were 
younger than patients usually are at diagnosis, AEs might occur even more 
frequently [5].  
However, based on these findings, cabazitaxel as 2nd-line therapy received a 
category 1 recommendation in the National Cancer Comprehensive Net-
work’s guidelines for prostate cancer [11] and a category A recommenda-
tions from the European Association of Urology [23]. The UpToDate Guide-
lines, on the other hand, issued only a 2B recommendation, which corre-
sponds to a weak recommendation [10]. 
Although the price for cabazitaxel still remains unknown in Austria, not on-
ly the costs for the drug itself have to be considered, but also those for pro-
phylactic therapy with G-CSF in high-risk patients (age ≥65 years, poor 
performance status, previous episodes of febrile neutropenia) as well as the 
treatment costs for side-effects, which might entail hospital admission.  
Open questions  which should be addressed in further clinical trials are the 
optimal dosing regimen, the comparison of cabazitaxel to docetaxel in the 
1st-line setting [24] and, as already mentioned, data on QoL. 
In summary, cabazitaxel is one of the first therapies which showed im-
provements of OS in patients with castration-resistant metastatic prostate 
cancer after failure of docetaxel therapy. But this result is put into perspec-
tive as this modest gain in OS was established in comparison to mitoxan-
trone, a therapy with an unknown impact on survival itself.  Moreover, very 
frequent serious and sometimes life-threatening AEs in combination with 
missing data on QoL prevent to date reliable estimates of the drug's true 
significance.  
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